Attached files

file filename
EX-99.2 - EXHIBIT 99.2 - Lipocine Inc.v456518_ex99-2.htm
EX-99.1 - EXHIBIT 99.1 - Lipocine Inc.v456518_ex99-1.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported):

January 9, 2017

 

 

 

LIPOCINE INC.

 

(Exact name of registrant as specified in its charter)

 

Commission File No. 001-36357

  

Delaware   99-0370688
(State or other jurisdiction of incorporation)   (IRS Employer Identification Number)

 

675 Arapeen Drive, Suite 202

Salt Lake City, Utah 84108

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (801) 994-7383

 

Former name or former address, if changed since last report: Not Applicable

______________________

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

  

Item 7.01Regulation FD Disclosures

 

On January 9, 2017, Lipocine Inc. issued a press release announcing the receipt of FDA guidance on the Phase 3 Program for LPCN 1107. The press release is filed as Exhibit 99.1 and is incorporated herein by reference.

 

Additionally, the Company has updated its corporate presentation that it uses when meeting with investors. The Company’s updated corporate presentation is attached hereto as Exhibit 99.2.

  

Item 9.01Financial Statements and Exhibits.

 

(d)Exhibits

 

The following exhibits are filed with this report:

 

Exhibit No. Description

99.1

Press Release Announcing the Receipt of FDA Guidance on the Phase 3 Program for LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth

 

99.2 Corporate Presentation

 

 

 

 

SIGNATURES

  

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

      LIPOCINE INC.
         
Date: January 9, 2017   By: /s/ Mahesh V. Patel
        Mahesh V. Patel
        President and Chief Executive Officer